The bill would tie prescription drug prices to some foreign markets, though not single-payer nations. Drug companies would be compelled to disclose sensitive pricing data. It adopts more limited pricing and coverage rules. The bill freezes drug formularies and requires more reporting from insurance companies and state agencies. The bill also regulates pharmacy benefit managers and prevents them from dictating some dispensing and pricing benchmarks.
